Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perseris (RBP-7000) Phase 2A in Stable Schizophrenia
NCT01677377Phase 2Completed
- Sponsor
- Indivior
- Start
- Aug 2012
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of risperidone in schizophrenia (3 cohorts), sponsored by Indivior. Primary endpoints: Treatment-Emergent Adverse Events, Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours and 4 more. Started Aug 2012; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01677377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01677377.